Although it remains elusive, it is tempting to assume that the frequent aggregation of RPB1 in tumor cells resistant to the transcription inhibitor epirubicin may be a consequence of a failure in the CCR4–NOT-dependent co-translational folding of RPB1. This evidence concerns the gene POLR2A and neoplasm.